Heerlen, NL, 29 Aug 2017 15:15 CEST
Royal DSM, a global science-based company active in health, nutrition and materials, informs its stakeholders that Thermo Fisher Scientific Inc. has completed the acquisition of Patheon N.V. (NYSE:PTHN), a company in which DSM held approximately 48.7 million ordinary shares.
Thermo Fisher has acquired all the shares of Patheon held by DSM for $35.00 per ordinary share in cash, resulting in a transaction payment to DSM of approximately $1.7 billion in cash. DSM has hedged the currency exposure of the transaction proceeds, thereby locking in cash proceeds of around €1.5 billion. The book value of DSM’s stake in Patheon is approximately €0.3 billion. The transaction will result in a net book profit of around €1.2bn in Q3 2017.
Together with the approximately €0.5 billion in cash that DSM already received in recent years, including the proceeds from the Initial Public Offering of Patheon, the total cash proceeds from the divestment of DSM’s custom manufacturing activities in Pharma in 2014 amount to approximately €2.0 billion.
Senior Communications Manager
+31 45 578 2420
Vice-President Investor Relations
+31 45 578 2864